Psoriasis Treatment: PASI-Guided Therapy from Topicals to Biologics — Cost, Top Hospitals & Success Rates | MyMedicPlus

Psoriasis is a chronic, immune-mediated, inflammatory skin disease characterised by aberrant keratinocyte proliferation, impaired epidermal differentiation, and angiogenesis, driven by a dysregulated adaptive immune response. The central pathogenic axis involves dendritic cell activation of Th17 CD4+ T cells, which produce IL-17A, IL-17F, IL-22, and TNF-α — cytokines that stimulate keratinocyte hyperproliferation (shortening the epidermal cell cycle from 28 days to 3–5 days) and recruitment of neutrophils and other inflammatory cells. IL-23 (produced by dendritic cells and macrophages) is an upstream regulator of the Th17 axis and is the target of newer, highly effective biologics.

Psoriasis affects approximately 2–3% of the global population and is associated with significant systemic comorbidities including psoriatic arthritis (PsA, in 20–30%), cardiovascular disease, metabolic syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, inflammatory bowel disease, and major depressive disorder. The psychological burden (stigma, itch, sleep disruption) is substantial and mandates quality-of-life assessment alongside skin severity scoring.

Severity assessment tools used in clinical practice:

• PASI (Psoriasis Area and Severity Index): Composite score (0–72) of erythema, induration, and scaling in four body regions weighted by area involvement. Mild <10; moderate 10–20; severe >20. PASI75/90/100 response at 10–16 weeks is the benchmark for biologic efficacy in clinical trials.
• BSA (Body Surface Area): Percentage of skin affected (>10% BSA = moderate-to-severe). One palm ≈ 1% BSA.
• DLQI (Dermatology Life Quality Index): 10-item validated questionnaire (0–30). Score >10 indicates very large effect on quality of life and qualifies for biologic therapy under NICE criteria alongside PASI >10 or BSA >10%.

NICE and EMA require both PASI >10 and DLQI >10 for biologic eligibility in moderate-to-severe plaque psoriasis, alongside failure or contraindication of phototherapy and at least one conventional systemic (methotrexate, ciclosporin, or acitretin).

Psoriasis encompasses several distinct clinical subtypes requiring tailored treatment approaches:

• Chronic plaque psoriasis (psoriasis vulgaris): The most common form, affecting 80–90% of patients. Well-demarcated, erythematous plaques with silvery scale on extensor surfaces (elbows, knees), scalp, lower back, and umbilicus. Treatment depends on extent, PASI, and DLQI. Localised disease: topical therapy. Extensive or moderate-to-severe disease: phototherapy, systemics, or biologics.
• Guttate psoriasis: Small (<1 cm), raindrop-like plaques following streptococcal throat infection in children and young adults. Often self-limiting (3–4 months); UVB phototherapy accelerates resolution. Streptococcal culture and throat swab; penicillin or amoxicillin if positive. Risk of transition to chronic plaque psoriasis in 30–40%.
• Pustular psoriasis (generalised von Zumbusch type): Sterile pustules on erythematous base; may be triggered by systemic corticosteroid withdrawal, hypocalcaemia, pregnancy, or infection. Life-threatening variant — requires hospitalisation, acitretin, ciclosporin, or IL-36 receptor antagonist (spesolimab — licensed for generalised pustular psoriasis flares). IL-17 biologics may worsen pustular psoriasis.
• Erythrodermic psoriasis: Diffuse erythema involving >90% BSA; systemic inflammatory response with temperature dysregulation and risk of high-output cardiac failure. Medical emergency: hospitalisation, fluid and electrolyte management, ciclosporin (preferred for rapid onset) or acitretin. Biologics used after stabilisation.
• Palmoplantar psoriasis and palmoplantar pustulosis: Highly disabling despite limited BSA; DLQI typically very high. PUVA, acitretin, and biologics (IL-17 agents) most effective.
• Nail psoriasis: Pitting, onycholysis, subungual hyperkeratosis; presents in 50% of plaque psoriasis patients and up to 90% of those with PsA. IL-17 and IL-23 biologics demonstrate highest NAPSI (Nail Psoriasis Severity Index) improvement.
• Scalp psoriasis: Topical corticosteroids in appropriate vehicles (shampoo, foam, gel) plus vitamin D analogues; NB-UVB via scalp comb; systemic therapy if widespread or unresponsive.

Treatment pathway is determined by disease severity using PASI, BSA, and DLQI:

• Mild psoriasis (PASI <10, BSA <10%, DLQI ≤10): Topical therapy alone is appropriate. Over-the-counter emollients, prescribed topical corticosteroids (potent or very potent), vitamin D analogues (calcipotriol), and their combination (Enstilar/Dovobet foam) are first-line. Patient education on the chronic relapsing-remitting nature, trigger avoidance (stress, streptococcal infections, beta-blockers, NSAIDs, lithium, withdrawal of systemic steroids), and emollient use is foundational.
• Moderate-to-severe psoriasis (PASI ≥10 or BSA ≥10% and DLQI >10): Qualifies for escalation to phototherapy or systemic therapy after inadequate topical response. NICE specifies phototherapy or conventional systemic therapy before biologic eligibility in most cases.
• Biologic eligibility (NICE criteria): PASI ≥10 and DLQI >10 plus either: (a) phototherapy failure, intolerance, or contraindication, or (b) conventional systemic failure, contraindication, or intolerance. At least one conventional systemic (methotrexate, ciclosporin, or acitretin) must have been trialled unless contraindicated. Pregnancy, active severe infection, latent TB (requiring 2-month LTBI treatment before anti-TNF initiation), and active malignancy require individual risk assessment.
• Special populations: Children (<18 years): etanercept, adalimumab, secukinumab, and ixekizumab licensed for paediatric plaque psoriasis. Pregnancy: ciclosporin (safest option); avoid methotrexate, acitretin, and most biologics in first trimester. Psoriatic arthritis co-existent: prefer IL-17 or IL-23 biologics or TNF inhibitors with evidence for both skin and joint outcomes.

Step 1: Topical Therapy (Mild Psoriasis)

• Topical corticosteroids: Cornerstone of mild psoriasis management. Potent (betamethasone valerate 0.1%) or very potent (clobetasol propionate 0.05%) preparations used for body plaques; milder agents (hydrocortisone 1%) for face and flexures to avoid atrophy and telangiectasia. Apply once or twice daily for 4–8 weeks; taper to avoid rebound.
• Vitamin D analogues (calcipotriol): Calcipotriol 0.005% cream or ointment; inhibits keratinocyte proliferation and promotes differentiation. Used alone or in combination with corticosteroids. Calcipotriol/betamethasone dipropionate (Dovobet gel, Enstilar foam) is the most widely prescribed combination, with superior efficacy to either monotherapy and improved adherence. Maximum 30% BSA (risk of hypercalcaemia if overused).
• Emollients: Daily thick emollient application (e.g., Epaderm, Diprobase, Doublebase) reduces scale, pruritus, and transepidermal water loss. Essential adjunct at all stages of treatment.
• Coal tar preparations: Anti-proliferative and anti-inflammatory; still used in Goeckerman regimen (tar + UVB). Second-line topical option; cosmetically less acceptable.

Step 2: Phototherapy (Moderate-to-Severe / Extensive Disease)

• Narrowband UVB (NB-UVB, 311–313 nm): Treatment of choice for widespread plaque and guttate psoriasis; 30+ sessions over 10–15 weeks. Clearance rates 60–75%; superior to broadband UVB. Safe in pregnancy; preferred over PUVA for most patients. Minimal erythemogenic dose (MED) calculated to personalise dosing. Maintenance therapy extends remission.
• PUVA (psoralen + UVA): 8-MOP oral psoralen + UVA irradiation; 20+ sessions over 8–10 weeks. Highly effective (clearance 80–90%); preferred for thick palmoplantar plaques, erythrodermic psoriasis, and phototherapy-resistant cases. Cumulative lifetime dose limit (1,500 J/cm² UVA) due to PUVA-related squamous cell carcinoma risk and ocular damage.

Step 3: Conventional Systemic Therapy

• Methotrexate (MTX): Anchor conventional systemic therapy for moderate-to-severe plaque psoriasis and psoriatic arthritis. Initial 5 mg test dose; escalate to 15–25 mg weekly (oral or SC). Folic acid 5 mg once weekly (or daily, omitting MTX day) reduces mucositis and hepatotoxicity. LFTs, FBC, renal function monitored regularly. Hepatotoxicity (fibrosis with cumulative dose >1.5 g) monitored by enhanced liver fibrosis (ELF) blood test (replacing routine biopsy). Teratogenic; contraception required in both sexes.
• Ciclosporin: Rapid onset (2–4 weeks); useful for severe flares, erythroderma, and as a bridging therapy. 2.5–5 mg/kg/day; limit to 1–2 years continuous use due to nephrotoxicity and hypertension. Monitor BP and creatinine fortnightly initially. Not suitable for long-term maintenance.
• Acitretin: Retinoid; particularly effective for palmoplantar, erythrodermic, and pustular psoriasis. 25–50 mg/day. Potent teratogen (2-year contraception after stopping). Dyslipidaemia and hepatotoxicity monitoring required. Synergistic with NB-UVB (Re-UVB or RePUVA) allowing lower doses of each modality.

Step 4: Biologic Therapy (Moderate-to-Severe; NICE-Eligible)

• IL-17A inhibitors: Secukinumab 300 mg SC monthly (ERASURE/FIXTURE trials; PASI90 at 16 weeks: 59–79%). Ixekizumab 80 mg SC every 2–4 weeks (UNCOVER trials; PASI100 in 35%). Bimekizumab (IL-17A/F dual inhibitor) 320 mg SC monthly (BE SURE, BE VIVID; highest PASI100 rates reported — 67% vs 46% for secukinumab at 16 weeks). Avoid in active Crohn's disease (IL-17 inhibition worsens IBD).
• IL-23 p19 inhibitors: Risankizumab 150 mg SC every 12 weeks (IMMvent, IMMhance; PASI90 at 52 weeks 81%). Guselkumab 100 mg SC every 8 weeks (VOYAGE 1/2; PASI90 75%). Tildrakizumab 100 mg SC every 12 weeks. Long dosing intervals (monthly to quarterly injections) and high durability make IL-23 inhibitors increasingly preferred for long-term management.
• TNF-α inhibitors: Adalimumab 80 mg loading, then 40 mg SC every 2 weeks (PASI75 at 16 weeks: 71%). Etanercept 25–50 mg SC twice weekly. Lower PASI90 rates than IL-17/IL-23 agents but long safety record and multiple approved biosimilars reduce cost substantially. Licensed for children ≥4 years (etanercept) and ≥4 years (adalimumab biosimilar).

Psoriasis treatment, when stepped up appropriately, achieves dramatic improvements in skin clearance, quality of life, and systemic inflammation:

• Topical combination (calcipotriol/betamethasone, Enstilar foam): PASI75 response in 50–65% at 4 weeks for mild-to-moderate psoriasis — superior to either monotherapy. High patient satisfaction and once-daily application improve adherence. Provides immediate access treatment without phototherapy appointments or monitoring requirements.
• NB-UVB phototherapy: Clearance rates 60–75% after 30+ sessions. Safe in pregnancy; no immunosuppression; suitable for paediatric patients. Remission periods of 3–6 months post-clearance in many patients. A practical option where biologics are unavailable or cost-prohibitive.
• Methotrexate: PASI75 in 35–45% at 16 weeks; effective for both skin and joint disease (psoriatic arthritis); lowest cost conventional systemic. Used as anchor systemic over years in many patients, with careful toxicity monitoring enabling safe long-term use.
• Secukinumab (ERASURE/FIXTURE trials): PASI90 in 59–79% and PASI100 in 28–44% at 16 weeks — significantly superior to etanercept and ustekinumab. Maintained efficacy at 52 weeks. Also effective for nail, scalp, and palmoplantar disease.
• Risankizumab (IMMhance, 52 weeks): PASI90 in 81% and PASI100 in 56% at 52 weeks — among the highest sustained response rates reported for any biologic. Quarterly injections after induction reduce patient burden.
• Bimekizumab (BE SURE trial, 16 weeks): PASI100 (complete skin clearance) in 67% versus 46% for secukinumab — a clinically meaningful superiority. Highest PASI90 and PASI100 rates reported across head-to-head biologic trials to date.
• Treat-to-target (PASI90 at week 16): European consensus recommends switching or intensifying therapy if PASI90 is not achieved at 16 weeks. This strategy prevents prolonged exposure to suboptimal treatments and drives earlier, more complete skin clearance with associated DLQI improvement.

Safety monitoring requirements vary significantly across psoriasis treatment modalities:

• Topical corticosteroids: Skin atrophy, telangiectasia, striae, and perioral dermatitis with prolonged use on sensitive skin areas. Tachyphylaxis (reduced efficacy with continuous use) managed by intermittent or weekend-only dosing. Systemic absorption causing HPA axis suppression is rare at recommended doses but possible if very potent agents are applied to large BSA.
• NB-UVB: Acute phototoxicity (erythema, blistering if over-dosed); cumulative lifetime risk of skin cancer (lower than PUVA; NB-UVB not strongly associated with melanoma). Eye protection required during treatment. Safe in pregnancy and children.
• PUVA: Acute: nausea from oral psoralen, phototoxicity. Long-term: squamous cell carcinoma risk (dose-dependent, significant above 200 sessions or 1,500 J/cm²); melanoma risk; photoageing; cataracts (prevent with wraparound UVA-blocking sunglasses on treatment days). Strict lifetime cumulative dose monitoring required.
• Methotrexate: Acute: nausea, mucositis, fatigue (reduced by SC administration and folic acid). Hepatotoxicity: fibrosis with cumulative dose >1.5 g; ELF test (pro-C3, hyaluronic acid, TIMP-1) replaces routine biopsy in most guidelines. Bone marrow suppression (FBC monitoring essential; avoid in impaired renal function). Teratogenic (men and women must use effective contraception during treatment and for 3 months after). Drug interactions: trimethoprim, NSAIDs, proton pump inhibitors may increase toxicity.
• Ciclosporin: Nephrotoxicity (irreversible if creatinine rises >30% above baseline — reduce dose or stop); hypertension (treat with nifedipine or amlodipine; avoid ACE inhibitors due to additive nephrotoxicity risk); hypertrichosis; gingival hyperplasia; headache; tremor. Risk of cutaneous SCC with prior PUVA. Not for long-term continuous use.
• Biologics (all classes): Increased infection risk — screen for latent TB (IGRA or Mantoux) and hepatitis B/C before starting; live vaccines contraindicated. Injection site reactions (common, usually mild). Monitor FBC and LFTs periodically.
• TNF-α inhibitors specifically: Risk of reactivating latent TB (LTBI requires 2-month LTBI treatment before anti-TNF initiation); demyelinating disease (contraindicated if multiple sclerosis); heart failure exacerbation (avoid if NYHA III/IV); lupus-like reactions.
• IL-17 inhibitors: Candidiasis (oral, oesophageal — 1–3%); IBD exacerbation (avoid in Crohn's disease); neutropenia (rare).
• IL-23 inhibitors: Favourable safety profile; infections slightly lower than IL-17 agents. No significant IBD risk. Very rare hypersensitivity reactions.

Psoriasis follow-up uses a treat-to-target strategy to ensure optimal outcomes and prompt therapy switching when needed:

Topical therapy:

• Review at 4–8 weeks to assess response; PASI/BSA/DLQI recorded at each visit
• If inadequate control after 8 weeks of optimised topical therapy, refer for phototherapy or systemic therapy assessment
• Emollient use and lifestyle modifications (alcohol, smoking cessation, trigger avoidance) reinforced at every visit

Phototherapy:

• Assess PASI and BSA at completion of course (typically 30–35 sessions); target PASI90 or IGA 0/1 (clear/almost clear)
• Maintenance NB-UVB (weekly or fortnightly) extends remission; maximum 200 sessions total lifetime for NB-UVB recommended by many centres
• If insufficient response at 30 sessions, consider augmenting with acitretin (Re-UVB) or transitioning to systemic/biologic therapy

Conventional systemics (methotrexate, ciclosporin):

• Methotrexate: FBC and LFTs at 2 weeks after any dose increase, then every 3 months. ELF test every 2 years or after cumulative dose milestones (>1.5 g, >3.5 g). Renal function every 6 months.
• Ciclosporin: Blood pressure and creatinine every 2 weeks for the first 3 months, then monthly. If creatinine rises >30% above baseline on two occasions, reduce dose by 25–50%; if creatinine remains elevated, discontinue.

Biologic therapy (treat-to-target at weeks 10–16):

• PASI, DLQI, and IGA assessed at week 10–16 (depending on biologic); target: PASI90 and/or DLQI ≤5
• If PASI improvement <50% at week 10–16: consider switching biologic class
• If PASI 50–74% at week 16: consider dose optimisation (interval shortening) or switch
• PASI ≥90 at week 16: continue current biologic at approved dosing interval
• Annual review: safety screening, DLQI, and PASI; consider stepping down or therapy breaks (drug holiday) for patients in sustained PASI100 with low disease burden
• TB screening repeated annually for patients on TNF inhibitors; hepatitis B monitoring for carriers on biologic therapy

Psoriasis treatment costs span a wide range from low-cost topicals to high-cost biologics:

• Topical therapy: Generic topical corticosteroids (betamethasone valerate 0.1% cream) $5–15/tube in the US; £1–5 on NHS prescription. Calcipotriol/betamethasone (Dovobet/Enstilar) ~$150–300/month in the US; NHS-prescribable at low cost. Emollients £3–10/pump in the UK; subsidised on prescription for psoriasis. Ongoing monthly cost is low compared with systemic therapies.
• Phototherapy: NB-UVB course (30–35 sessions): $2,000–5,000 private in the US; ~£500–2,000 in UK private; NHS-funded. Requires 3 visits per week for 10–12 weeks — travel and time cost significant for patients. Home phototherapy units ($2,000–5,000 one-time purchase) may be cost-effective for long-term users.
• Methotrexate: Generic methotrexate tablets: $10–30/month in the US; £1–5/month NHS. SC formulations (Metoject) more expensive but improve tolerability and bioavailability. Monitoring costs (quarterly LFTs, FBC, ELF tests) add $200–500/year. Highly cost-effective systemic option.
• Ciclosporin: Generic ciclosporin $100–300/month. Monitoring (monthly BP, creatinine) adds cost. Time-limited to 1–2 years continuous use.
• Biologic therapy: Brand adalimumab ~$5,000–8,000/month in the US; adalimumab biosimilars (Hadlima, Hyrimoz) 30–50% cheaper. Secukinumab ~$5,000–6,500/month (no biosimilar yet). Risankizumab ~$5,500–7,000/month (quarterly dosing reduces total injections). Bimekizumab ~$6,000–8,000/month. NHS-funded biologics for eligible patients under NICE technology appraisals (TA methotrexate intolerant / inadequate response pathway) at negotiated confidential discounted prices.
• Medical tourism: Biologic treatment in India, Turkey, and Thailand costs 60–80% less than US private rates, with locally manufactured or imported biosimilars used at certified dermatology centres. Monitoring and follow-up must be planned across borders carefully.

Several targeted oral agents and novel biologics expand the treatment landscape beyond conventional therapy:

• Apremilast (PDE4 inhibitor): Oral tablet 30 mg twice daily. Inhibits phosphodiesterase-4, reducing intracellular cAMP breakdown and downstream inflammatory cytokine production (TNF-α, IL-17, IL-23). Licensed for moderate-to-severe plaque psoriasis and PsA. PASI75 in 33% at 16 weeks (ESTEEM 1/2 trials) — lower than biologics but with an oral route, no immunosuppression monitoring, and no LTBI screening requirement. Suitable as a step between conventional systemics and biologics; particularly useful where infection risk precludes biologic therapy.
• Deucravacitinib (TYK2 inhibitor): Oral TYK2 (tyrosine kinase 2) inhibitor; 6 mg once daily. TYK2 selectively mediates IL-12, IL-23, and type I interferon signalling. POETYK PSO-1/2 trials: PASI75 in 53–58% at 16 weeks, significantly superior to apremilast. More selective than pan-JAK inhibitors (lower infection risk profile); no LTBI screening required in current FDA prescribing information. Approved by FDA (Sotyktu) for moderate-to-severe plaque psoriasis in adults.
• Spesolimab (IL-36 receptor antagonist): IV infusion for acute generalised pustular psoriasis (GPP) flares. EFFISAYIL-1 trial: 54% of patients with GPP achieved clear skin at week 1 versus 6% placebo. A first-in-class therapy for this life-threatening subtype where IL-36 cytokines (IL-36α, IL-36β, IL-36γ) are the primary driver.
• JAK inhibitors (baricitinib, upadacitinib): Oral pan-JAK or JAK1-selective inhibitors licensed for PsA; under investigation for skin psoriasis. Higher infection risk profile (MACE, VTE) requires careful patient selection per EMA and FDA boxed warnings.
• Lifestyle and complementary approaches: Structured weight loss in overweight patients with psoriasis significantly improves PASI response to biologic therapy (OSAGE trial). Smoking cessation, alcohol reduction, and stress management (mindfulness-based CBT) are evidence-based adjuncts. Low-quality evidence supports turmeric and fish oil supplementation; no supplement replaces or substitutes licensed treatment. Balneotherapy (Dead Sea or salt bath therapy with UVB) may provide modest improvement in mild-to-moderate psoriasis.